Compass Therapeutics announced that its Phase 2/3 clinical trial results for tovecimig, a bispecific antibody combined with paclitaxel, in advanced biliary tract cancer will be presented orally at the ESMO Congress 2026 in Madrid. The presentation, led by Dr. Nilofer Azad from Johns Hopkins University, will highlight data from the COMPANION-002 trial assessing the drug's effectiveness. This event marks a significant step in showcasing Compass's oncology pipeline and advancing treatment options for this difficult-to-treat cancer. Further details will be shared at the congress in October 2026.
Hilton Grand Vacations (HGV) has been upgraded to a 'strong buy' with a price target of $55, indicating over 50% potential upside. Despite recent stock declines and weak vacation ownership interest (VOI) sales, HGV's stable recurring revenue and impr...
Cardano's ADA surged 10% in 24 hours to over 27 cents, its highest level since May, outperforming Bitcoin and Ether which rose modestly. The rally is likely driven by excitement around Cardano's new RealFi institutional credit product offering up to ...
Banka has integrated Bitcoin trading into its mobile app, allowing customers to buy and sell BTC directly through their bank accounts without opening a separate exchange account. Users can start trading with as little as 500 koruna (about $23) and tr...
Ethereum trader DonAlt opened a large long position around $1,878 in mid-August and has since moved to a HODL strategy, planning to take most profits near $3,000. Although his technical analysis suggests ETH could rise significantly higher, he prefer...
Two Bitcoin wallets that had been inactive for about 13 years recently sent a small test transaction of 0.0005 BTC, worth around $43. These wallets hold a total of 1,346 BTC, currently valued at approximately $115 million, acquired when Bitcoin was p...
